XU Gaoqi, YANG Dihong, XIN Wenxiu, DING Haiying, ZHU Junfeng, ZHONG Like, HE Chaoneng, FANG Luo. Research Progress of Pharmacokinetics Studies of Anti-tumor Drugs in Patients with Third Space Fluid[J]. Chinese Journal of Modern Applied Pharmacy, 2023, 40(12): 1596-1602. DOI: 10.13748/j.cnki.issn1007-7693.20231440
    Citation: XU Gaoqi, YANG Dihong, XIN Wenxiu, DING Haiying, ZHU Junfeng, ZHONG Like, HE Chaoneng, FANG Luo. Research Progress of Pharmacokinetics Studies of Anti-tumor Drugs in Patients with Third Space Fluid[J]. Chinese Journal of Modern Applied Pharmacy, 2023, 40(12): 1596-1602. DOI: 10.13748/j.cnki.issn1007-7693.20231440

    Research Progress of Pharmacokinetics Studies of Anti-tumor Drugs in Patients with Third Space Fluid

    • Third space fluid(TSF) is a common complication of advanced malignancies, including malignant pleural effusion, malignant ascites, intracranial effusion, and pelvic effusion, etc. The pharmacokinetics(PK) of anti-tumor drugs in vivo are influenced by various factors, and TSF is one of the potential factors that contributes to PK variations, which may consequently affect the efficacy and safety of anti-tumor drugs. This paper aimed to comprehensively investigate PK studies related to anti-tumor drugs in patients with malignant tumors accompanied by TSF. The paper summarized the PK characteristics of common cytotoxic drugs, small molecule targeted drugs, and monoclonal antibodies in both blood and TSF.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return